Abstract: A process for the preparation of resorcinol using the meta-phenylenediamine hydrolysis reaction is provided. A reactor vessel made of a suitable material such as zirconium or a zirconium alloy is used, thus resisting corrosion and formation of resinous materials.
Abstract: Novel pyrrolo[3,2-d]pyrimidine derivatives of the following general formula
are disclosed. These compounds are useful in the treatment of bacterial infections such as Toxoplasmosis gondii and Pneumocystis carinii, and various types of cancer, through their action on dihydrofolate reductase and thymidylate syndmase enzymes. Methods of inhibiting these enzymes, by administration of these compounds, are also disclosed.
Abstract: An isolated cDNA molecule comprising an amino acid sequence encoding an amino-terminal protein fragment of murine glycoprotein 110 is disclosed. Therapeutic methods for treating tumor-bearing patients are also disclosed, as are prophylactic methods for vaccinating patients. An animal model for studying tumors is also disclosed.
Type:
Grant
Filed:
July 21, 1997
Date of Patent:
February 4, 2003
Assignee:
University of Pittsburgh of the Commonwealth System of Higher
Education
Inventors:
Albert B. DeLeo, Douglas Loftus, Ettore Appella
Abstract: This invention provides deformable low density trauma mitigation or pressure reducing composition comprising a viscous fluid and a plurality of macroparticulates and, optionally, microparticulates dispersed within the viscous fluid. The viscous fluid can comprise a water/oil emulsion, a glycerin/water mixture, a plasticizer or the like. In a further embodiment the composition comprises a viscous fluid and an enhancer which is a polytetrafluoroethylene-molybdenum disulfide combination.
Abstract: A radiation-curable ink, a method of making the ink, a thermal transfer printer ribbon having a radiation-curable ink layer, and a thermal transfer printer with an actinic energy source are provided. A method of thermal transfer printing using an ink ribbon having radiation-curable components is also provided. The radiation curable components of the ink can be thermally dried and are cured after printing of an image on a receiving article.
Type:
Grant
Filed:
August 2, 2000
Date of Patent:
November 5, 2002
Assignee:
Sony Chemical Corporation of America
Inventors:
Jeffrey F. Taylor, John T. Whalen, Lara A. Reed, Richard G. Crooks, Marlee A. Vrbanic
Abstract: Methods for preparing formaldehyde-free resorcinol resins are disclosed. The methods generally comprise reacting resorcinol first with dicyclopentadiene and then reacting that mixture with an olefinic compound. The resins produced by this method are also disclosed, as are rubber compositions utilizing the present resins. The resins are characterized as having a free resorcinol content of about 1 wt. % or less, and yielding a suitable softening point when used in rubber applications.
Abstract: Pharmaceutical compositions comprising a macromolecular pharmaceutical agent in mixed micellar form are disclosed. The mixed micelles are formed from an alkali metal alkyl sulfate, and at least three different micelle-forming compounds as described in the specification. Micelle size ranges between about 1 and 10 nanometers. Methods for making and using the compositions are also disclosed. A preferred method for administering the present composition is through the buccal region of the mouth.
Abstract: A mixed micellar aerosol pharmaceutical formulation includes a micellar proteinic pharmaceutical agent, an alkali metal lauryl sulphate, at least three micelle forming compounds, a phenol and a propellant. The micelle forming compounds are selected from the group consisting of lecithin, hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, glycolic acid, lactic acid, chamomile extract, cucumber extract, oleic acid, linoleic acid, linolenic acid, monoolein, monooleates, monolaurates, borage oil, evening of primrose oil, menthol, trihydroxy oxo cholanyl glycine and pharmaceutically acceptable salts thereof, glycerin, polyglycerin, lysine, polylysine, triolein, polyoxyethylene ethers and analogues thereof, polidocanol alkyl ethers and analogues thereof. The amount of each micelle forming compound is present in a concentration of from 1 to 20 wt./wt. % of the total formulation, and the total concentration of micelle forming compounds are less than 50 wt./wt. % of the formulation.
Abstract: Novel sulfatase inhibitor compounds useful in the treatment of estrogen dependent illnesses are disclosed. These compounds generally comprise a steroid nucleus substituted at the C17 position. Methods for synthesizing these compounds and using them in the therapeutic and/or prophylactic treatment of a patient are also disclosed.
Type:
Grant
Filed:
November 8, 2001
Date of Patent:
August 20, 2002
Assignees:
Duquesne University of the Holy Ghost, Kyowa Hakko Kogyo Co., Ltd.
Abstract: A mixed micellar pharmaceutical formulation includes a micellar proteinic pharmaceutical agent, an alkali metal lauryl sulphate, alkali metal salicylate, a pharmaceutically acceptable edetate and at least one absorption enhancing compounds. The absorption enhancing compounds are selected from the group consisting of lecithin, hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, octylphenoxypolyethoxyethanol, glycolic acid, lactic acid, chamomile extract, cucumber extract, oleic acid, linolenic acid, borage oil, evening of primrose oil, trihydroxy oxo cholanylglycine, glycerin, polyglycerin, lysine, polylysine, triolein and mixtures thereof. The amount of each absorption enhancing compound is present in a concentration of from 1 to 10 wt./wt. % of the total formulation, and the total concentration of absorption enhancing compounds are less than 50 wt./wt. % of the formulation. A method for administering insulin to the buccal mucosa using a metered dose inhaler is also disclosed.
Abstract: Novel sulfatase inhibitor/estrogen receptor blocker compounds useful in the treatment of estrogen dependent illnesses are disclosed. The compounds generally comprise a sulfamate moiety and an aromatic, estrogen receptor blocker moiety. Methods for synthesizing these compounds and using them in the therapeutic and/or prophylactic treatment of an estrogen-dependent disease are also disclosed.
Abstract: This invention discloses compounds, and pharmaceutically acceptable salts, solvates and prodrugs thereof, useful in therapeutically and/or prophylactically treating patients with an illness. Such illnesses include cancer, and secondary infections caused by Pneumocystis carinii, Toxoplasma gondii, Mycobacterium tuberculosis, and Mycobacterium avium. The compounds themselves, methods of making these compounds, and methods of using these compounds are all disclosed. The compounds include 5-thiapyrimidines.
Abstract: This invention discloses compounds, and pharmaceutically acceptable salts thereof, useful in therapeutically and/or prophylactically treating patients with an illness. Such illnesses include cancer, and secondary infections caused by Pneumocystis carinii and Toxoplasmosis gondii in immunocompromised patients. The compounds themselves, methods of making these compounds, and methods of using these compounds are all disclosed.
Abstract: A wood treatment material having a synergistic combination of fungicides including boron-containing compounds, organo-iodine compounds and amine-oxides is provided. This combination is shown to be especially effective in providing resistance to decay, mold and mildew when wood is treated with this combination. Also provided is wood treated by this combination, and a method of treatment for composite wood.
Type:
Grant
Filed:
January 5, 2001
Date of Patent:
July 9, 2002
Assignee:
Kop-Coat, Inc.
Inventors:
Brian Marks, Alan S. Ross, Hans A. Ward
Abstract: Novel sulfatase inhibitor compounds useful in the treatment of estrogen dependent illnesses are disclosed. These compounds generally comprise a steroid nucleus substituted at the C17 position. Methods for synthesizing these compounds and using them in the therapeutic and/or prophylactic treatment of a patient are also disclosed.
Type:
Grant
Filed:
August 3, 2001
Date of Patent:
June 4, 2002
Assignees:
Duquesne University of the Holy Ghost, Kyowa Hakko Kogyo Co., Ltd.
Abstract: A substrate system for receiving a deposit of sprayed metal droplets including a movable outer substrate on which the sprayed metal droplets are deposited. The substrate system also includes an inner substrate disposed adjacent the outer substrate where the sprayed metal droplets are deposited on the outer substrate. The inner substrate includes zones of differing thermal conductivity to resist substrate layer porosity and to resist formation of large grains and coarse constituent particles in a bulk layer of the metal droplets which have accumulated on the outer substrate. A spray forming apparatus and associated method of spray forming a molten metal to form a metal product using the substrate system of the invention is also provided.
Abstract: Pharmaceutical compositions comprising a macromolecular pharmaceutical agent in mixed micellar form are disclosed. The mixed micelles are formed from an alkali metal alkyl sulfate, and at least three different micelle-forming compounds as described in the specification. Micelle size ranges between about 1 and 10 nanometers. Methods for making and using the compositions are also disclosed. A preferred method for administering the present composition is through the buccal region of the mouth.
Abstract: Novel sulfatase inhibitor compounds useful in the treatment of estrogen dependent illnesses are disclosed. These compounds generally comprise a steroid nucleus substituted at the C17 position. Methods for synthesizing these compounds and using them in the therapeutic and/or prophylactic treatment of a patient are also disclosed.
Type:
Grant
Filed:
January 24, 2000
Date of Patent:
April 23, 2002
Assignees:
Duquesne University of the Holy Ghost, Kyowa Hakko Kogyo Co., Ltd.
Abstract: Pharmaceutical compositions comprising a macromolecular pharmaceutical agent in micellar form are disclosed. The micelles are formed from an alkali metal alkyl sulfate, and at least one additional micelle-forming compound as described in the specification. An alkali metal salicylate and a pharmaceutically acceptable edetate are also included in the composition. Micelle size ranges between about 1 and 10 nanometers. Methods for making and using the compositions are also disclosed.
Abstract: A pharmaceutical composition solubilized in a propellant that can be administered buccally or to the lungs using a metered dose dispenser is provided. The composition comprises a pharmaceutical agent; glycerin and/or polyglycerin; phenol and/or methyl phenol; and at least one absorption enhancing compound. A pressurized container with the composition and a methods of making the composition are also provided.